These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27695947)

  • 41. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival?
    Altındağ SD; Yiğit S; Şen S
    Turk J Med Sci; 2022 Oct; 52(5):1569-1579. PubMed ID: 36422476
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers.
    Corrado G; Laquintana V; Loria R; Carosi M; de Salvo L; Sperduti I; Zampa A; Cicchillitti L; Piaggio G; Cutillo G; Falcioni R; Vizza E
    J Exp Clin Cancer Res; 2018 Jul; 37(1):139. PubMed ID: 29980240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High L1CAM expression predicts poor prognosis of patients with endometrial cancer: A systematic review and meta-analysis.
    Guo M; Gong H; Nie D; Li Z
    Medicine (Baltimore); 2021 Apr; 100(13):e25330. PubMed ID: 33787629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
    Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
    Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
    [No Abstract]   [Full Text] [Related]  

  • 46. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
    Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
    Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer.
    Liu Y; Meng F; Xu Y; Yang S; Xiao M; Chen X; Lou G
    Int J Gynecol Cancer; 2013 Feb; 23(2):304-11. PubMed ID: 23321718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective analysis of prognostic variables and clinical outcomes in surgically staged intermediate risk endometrial carcinoma.
    Zhang GY; Wu LY; Li B; Huang MN; Zhang R; Li XG
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):309-16. PubMed ID: 23540792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
    Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
    Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer.
    Alexander-Sefre F; Nibbs R; Rafferty T; Ayhan A; Singh N; Jacobs I
    Int J Gynecol Cancer; 2009 Aug; 19(6):1074-9. PubMed ID: 19820371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
    Edqvist PH; Huvila J; Forsström B; Talve L; Carpén O; Salvesen HB; Krakstad C; Grénman S; Johannesson H; Ljungqvist O; Uhlén M; Pontén F; Auranen A
    Gynecol Oncol; 2015 Jun; 137(3):529-37. PubMed ID: 25858696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.
    Brüning A; Jückstock J; Blankenstein T; Makovitzky J; Kunze S; Mylonas I
    Histol Histopathol; 2010 Nov; 25(11):1447-56. PubMed ID: 20865667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
    Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
    Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas.
    Mancusi de Carvalho JP; Salim RC; Carvalho FM; Nogueira Dias Genta ML; Baracat EC; Carvalho JP
    J Clin Pathol; 2020 Nov; 73(11):748-753. PubMed ID: 32366597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. L1CAM Expression in Microcystic, Elongated, and Fragmented (MELF) Glands Predicts Lymph Node Involvement in Endometrial Carcinoma.
    Arciuolo D; Travaglino A; Santoro A; Scaglione G; D'Alessandris N; Valente M; Inzani F; Accarino R; Piermattei A; Benvenuto R; Raffone A; Nero C; Pelligra S; Fanfani F; Mascolo M; Zannoni GF
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
    Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
    J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression.
    Park S; Cho Y; Kim HS
    Anticancer Res; 2023 Oct; 43(10):4559-4571. PubMed ID: 37772557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.
    Ørtoft G; Lausten-Thomsen L; Høgdall C; Hansen ES; Dueholm M
    J Gynecol Oncol; 2019 Sep; 30(5):e84. PubMed ID: 31328462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Huvila J; Laajala TD; Edqvist PH; Mardinoglu A; Talve L; Pontén F; Grénman S; Carpén O; Aittokallio T; Auranen A
    Gynecol Oncol; 2018 Apr; 149(1):173-180. PubMed ID: 29486992
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.